AstraZeneca's experimental COPD drug tozorakimab succeeded in two late-stage clinical trials.

What it means

AstraZeneca's experimental drug tozorakimab, a monoclonal antibody designed to reduce exacerbations in chronic obstructive pulmonary disease (COPD), met its primary endpoints in two Phase III clinical trials (TITANIA and OBERON). The results suggest the drug can meaningfully cut the frequency of COPD flare-ups, a major cause of hospitalization and disease progression, positioning it as a potential new treatment option for the millions of people with this incurable lung condition.

Accuracy & sourcesGrounded

The claim is solid, reported by multiple reputable outlets (CNBC, STAT News, Bloomberg, ABC News) citing AstraZeneca's own press release or data presentation. The reporting sits close to the primary source—the company's announcement of the trial results—so the core fact of two successful late-stage trials is well-supported.

How new

Genuinely new: the trial results were first reported on September 8, 2026, and the underlying material is current, not a resurfacing of older data.

Go deeper

• CNBC article
• STAT News article